8-K
MARIMED INC. (MRMD)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 OR 15(d) of
The
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 27, 2022
| MARIMED INC. | ||
|---|---|---|
| (Exact<br> name of registrant as specified in its charter) | ||
| Delaware | 0-54433 | 27-4672745 |
| --- | --- | --- |
| (State<br> or other jurisdiction | (Commission | (IRS<br> Employer |
| of<br> incorporation) | File<br> Number) | Identification<br> No.) |
| 10 Oceana Way, Norwood, Massachusetts | 02062 | |
| --- | --- | |
| (Address<br> of principal executive offices) | (Zip<br> Code) |
Registrant’s telephone number, including area code: (617) 795-5140
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ☐ | Written<br> communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|---|---|
| ☐ | Soliciting<br> material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement<br> communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement<br> communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act: None.
| Title<br> of each class | Ticker<br> symbol(s) | Name<br> of each exchange on which registered |
|---|---|---|
| Not<br> Applicable. | Not<br> Applicable. | Not<br> Applicable. |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item5.07. Submission of Matters to Vote of Security Holders.
On October 27, 2022, MariMed Inc. (the “Company”) held its 2022 Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, stockholders:
| ● | re-elected<br> the Company’s five directors to serve until the Company’s next annual meeting of stockholders or until their respective<br> successors have been duly elected and qualified (the “Election of Directors”); and |
|---|---|
| ● | approved,<br> on an advisory basis, the appointment of M&K CPAs PLLC as the Company’s independent auditors for the 2022 fiscal year (“Advisory<br> approval of Auditors”). |
The specific votes were as follows:
| 1. | The<br> Election of Directors: | ||
|---|---|---|---|
| VOTES | |||
| --- | --- | --- | --- |
| For | WITHHELD | BROKER NON-VOTE | |
| Robert<br>Fireman | 138,918,236 | 1,753,185 | 88,203,033 |
| Jon<br> R. Levine | 138,002,182 | 2,669,239 | 88,203,033 |
| David<br> Allen | 137,829,140 | 2,842,281 | 88,203,033 |
| Edward<br> Gildea | 137,817,074 | 2,854,347 | 88,203,033 |
| Eva<br> Selhub, M.D | 139,043,020 | 1,628,401 | 88,203,033 |
| 2. | Advisory<br> approval of Auditors: | ||
| --- | --- | ||
| VOTES | |||
| --- | --- | --- | |
| FOR | AGAINST | ABSTAIN | |
| 227,091,546 | 537,750 | 1,245,158 |
* * * * *
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| MARIMED<br> INC. | ||
|---|---|---|
| Dated:<br> October 31, 2022 | ||
| By: | /s/ Susan M. Villare | |
| Susan<br> M. Villare, Chief Financial Officer |